https://www.selleckchem.com/pr....oducts/itacitinib-in
Treatment options for secondary progressive multiple sclerosis (SPMS) are limitedly investigated. We aimed to compare the efficacy of rituximab (RTX) and glatiramer acetate (GA) in SPMS patients. This open, randomized clinical trial was conducted on 84 SPMS patients, assigned to receive RTX or GA for 12months. In RTX group, patients received 1g intravenous RTX primarily and then every 6-months. In GA group, patients received 40mg of GA 3-times/week subcutaneously. We measured EDSS as the primary outcome and neuroimaging fin
Like
Comment
Share
